Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.60 |
| ▸ | PI4KA | P42356 | 4/20 | 0.60 |
| ▸ | PI4K2B | Q8TCG2 | 4/20 | 0.60 |
| ▸ | PI4K2A | Q9BTU6 | 4/20 | 0.60 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.49 |
| ▸ | NSD2 | O96028 | 2/20 | 0.47 |
| ▸ | NSD3 | Q9BZ95 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arprinocid SCHEMBL31379008 | 1.00 | ADORA2A (0.60) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| Arprinocid SCHEMBL8375355 | 1.00 | ADORA2A (0.60) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| Arprinocid SCHEMBL31025603 | 1.00 | ADORA2A (0.60) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL10962832 | 0.91 | ADORA2A (0.68) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL11016348 | 0.91 | ADORA2A (0.63) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| Arprinocid SCHEMBL29801468 | 0.88 | PI4KA (0.45) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL11812620 | 0.85 | ADORA2A (0.60) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL11807952 | 0.85 | ADORA2A (0.60) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL10408838 | 0.82 | PDE4A (0.67) | LMNASMN1; SMN2NPSR1TSHRALDH1A1 | |
| SCHEMBL11151054 | 0.82 | SMN1; SMN2 (0.67) | LMNASMN1; SMN2NPSR1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 325 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11246836-B2 | Intramuscular depot of decoquinate compositions and method of prophylaxis and treatment thereof | BLUELIGHT PHARMATECH CO., LTD. (CN) | 2022-02-15 | — | — | US | claimed |
| US-20210059946-A1 | INTRAMUSCULAR DEPOT OF DECOQUINATE COMPOSITIONS AND METHOD OF PROPHYLAXIS AND TREATMENT THEREOF | CAS LAMVAC (GUANGZHOU) BIOMEDICAL TECHNOLOGY CO., LTD. (CN) | 2021-03-04 | — | — | US | claimed |
| CN-110495523-A | A kind of antibiotic-free, veterinary drug preparation of no drug residue and preparation method thereof | NANJING HUIMU BIOTECHNOLOGY CO LTD | 2019-11-26 | — | — | CN | claimed |
| WO-2019218305-A1 | INTRAMUSCULAR DEPOT OF DECOQUINATE COMPOSITIONS AND METHOD OF PROPHYLAXIS AND TREATMENT THEREOF | Bluelight Pharmatech Co., Ltd (CN) | 2019-11-21 | — | — | WO | claimed |
| CN-109496152-A | The method of the intramuscular inventory and its prevention and treatment of deccox composition | 广州蓝亮医药科技有限公司 | 2019-03-19 | — | — | CN | claimed |
| US-20170291886-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | NEOCULI PTY LTD (AU) | 2017-10-12 | — | — | US | claimed |
| CN-103099810-B | Purine anti-coccidiosis medicine and preparation method thereof | GUANGZHOU SCAU EX VETERINARY MEDICINE CO LTD | 2015-04-29 | — | — | CN | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| CN-103061181-B | Complex enzyme preparation and technique for preparing dissolving pulp by using same | YELLOW RIVER DELTA JINGBO CHEMICAL RESEARCH INSTITUTE CO., LTD. (CN) | 2014-10-22 | — | — | CN | claimed |
| CN-103099810-A | Purine anti-coccidiosis medicine and preparation method thereof | GUANGZHOU SCAU EX VETERINARY MEDICINE CO LTD | 2013-05-15 | — | — | CN | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| CN-1196485-C | composition for controlling parasitic protozoa | BAYER AG (DE) | 2005-04-13 | — | — | CN | claimed |
| EP-0828487-B1 | AGENTS FOR USE AGAINST PARASITIC PROTOZOA | BAYER AG (DE) | 2003-11-26 | — | — | EP | claimed |
| US-RE31429-E | ANTICOCCIDIAL AGENTS, RANEY NICKEL DESULFURIZATION | MERCK & CO., INC. (US) | 1983-10-25 | — | — | US | claimed |
| US-4171440-A | Process for purification of 9-(2,6-dihalobenzyl)adenines | MERCK & CO., INC. (US) | 1979-10-16 | — | — | US | claimed |
| US-4100159-A | REACTING 2,6-DIHALOBENZYL HALIDES WITH A SALT OF ADENINE IN PRESENCE OF ONIUM SALT PHASE TRANSFER CATALYST | MERCK & CO., INC. (US) | 1978-07-11 | — | — | US | claimed |
| US-3953597-A | POULTRY FEEDS | INTERNATIONAL MINERALS & CHEMICAL CORPORATION (US) | 1976-04-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291886-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | DPM1, ABCB11, PIGS | ADORA2A 2439/4885PI4KA 4533/4885PI4K2B 4771/4885 |
| US-20210059946-A1 | INTRAMUSCULAR DEPOT OF DECOQUINATE COMPOSITIONS AND METHOD OF PROPHYLAXIS AND TREATMENT THEREOF | HMGCR, DECR1, GYS1 | ADORA2A 1520/4885PI4KA 2099/4885PI4K2B 2671/4885 |
| US-11246836-B2 | Intramuscular depot of decoquinate compositions and method of prophylaxis and treatment thereof | HMGCR, DECR1, GYS1 | ADORA2A 1520/4885PI4KA 2099/4885PI4K2B 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.